Celgene (NASDAQ:CELG)‘s stock had its “buy” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

Several other research firms also recently issued reports on CELG. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “strong-buy” rating and set a $102.00 price objective for the company in a research note on Wednesday, August 1st. Mizuho restated a “buy” rating and issued a $129.00 price objective on shares of Celgene in a research note on Tuesday, July 31st. Cantor Fitzgerald assumed coverage on shares of Celgene in a research note on Monday, October 1st. They issued an “overweight” rating and a $100.00 price objective for the company. BidaskClub upgraded shares of Celgene from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Finally, Morgan Stanley upped their price objective on shares of Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a research note on Friday, July 27th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. Celgene presently has a consensus rating of “Buy” and a consensus target price of $121.42.

NASDAQ CELG opened at $84.23 on Thursday. The company has a debt-to-equity ratio of 5.76, a current ratio of 1.52 and a quick ratio of 1.40. Celgene has a 1 year low of $74.13 and a 1 year high of $140.20. The firm has a market capitalization of $62.94 billion, a price-to-earnings ratio of 12.31, a P/E/G ratio of 0.54 and a beta of 1.30.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.70 billion. During the same quarter in the prior year, the firm posted $1.82 earnings per share. Celgene’s revenue for the quarter was up 16.6% on a year-over-year basis. On average, sell-side analysts anticipate that Celgene will post 7.64 EPS for the current fiscal year.

In other news, Director John H. Weiland purchased 5,575 shares of the business’s stock in a transaction that occurred on Tuesday, August 7th. The stock was purchased at an average cost of $89.73 per share, with a total value of $500,244.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ernest Mario sold 12,000 shares of the stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the transaction, the director now directly owns 44,413 shares of the company’s stock, valued at $4,100,208.16. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Thompson Rubinstein Investment Management Inc. OR raised its holdings in Celgene by 19.5% during the third quarter. Thompson Rubinstein Investment Management Inc. OR now owns 40,447 shares of the biopharmaceutical company’s stock worth $3,620,000 after purchasing an additional 6,612 shares in the last quarter. Lourd Capital LLC purchased a new position in Celgene during the third quarter worth about $307,000. Factory Mutual Insurance Co. raised its holdings in Celgene by 2.6% during the third quarter. Factory Mutual Insurance Co. now owns 593,400 shares of the biopharmaceutical company’s stock worth $53,104,000 after purchasing an additional 14,900 shares in the last quarter. Beech Hill Advisors Inc. raised its holdings in Celgene by 28.4% during the third quarter. Beech Hill Advisors Inc. now owns 53,975 shares of the biopharmaceutical company’s stock worth $4,830,000 after purchasing an additional 11,925 shares in the last quarter. Finally, Gyroscope Capital Management Group LLC raised its holdings in Celgene by 356.3% during the third quarter. Gyroscope Capital Management Group LLC now owns 115,000 shares of the biopharmaceutical company’s stock worth $10,036,000 after purchasing an additional 89,800 shares in the last quarter. 73.11% of the stock is owned by hedge funds and other institutional investors.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Leveraged Buyout (LBO)

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.